ABBV vs INTC: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Intel Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-29.
AbbVie Inc. · Healthcare
$197.69
+6.3% upside to fair value
Grade C
High Quality
VS
Intel Corporation · Technology
$82.54
-5.4% upside to fair value
Grade D
QuantHub Verdict
ABBV has more upside to fair value
(+6.3%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
INTC |
| Current Price |
$197.69 |
$82.54 |
| Fair Value Estimate |
$210.22 |
$78.09 |
| Upside to Fair Value |
+6.3%
|
-5.4%
|
| Market Cap |
$349.7B |
$414.4B |
| Forward P/E |
83.3x
|
-132.2x
|
| EV / EBITDA |
23.4x
|
50.1x
|
| Price / Sales |
5.7x
|
7.7x
|
| Price / FCF |
18.7x
|
-132.9x
|
| Revenue Growth YoY |
+10.0%
|
+7.2%
|
| Gross Margin |
70.2%
|
35.4%
|
| Operating Margin |
26.7%
|
-9.4%
|
| Return on Equity |
-361.6%
|
-3.0%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.35%
|
—
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
Intel Corporation is a leading semiconductor company transitioning to a foundry business model while maintaining significant revenue from client computing and data center segments. Despite a strong market position and experienced leadership, the company faces earnings pressure with a 354% decline in earnings in the most recent quarter and negative margins. The stock trades at $82.54, which is 5.4…
Accumulation Zones
| Metric |
ABBV |
INTC |
| Zone Low |
$157.66 |
$58.57 |
| Zone High |
$178.69 |
$66.38 |
| In Buy Zone? |
No
|
No
|